Test Price
2,800 AEDโ Home Collection Available
๐ Results in 3โ4 Weeks
AKAP9 Gene Long QT Syndrome Type 11 Genetic Test in UAE | AED 2,800
Executive Summary & Core Metrics
The AKAP9 gene sequencing test utilizes next-generation sequencing (NGS) technology to analyze the complete coding region of the AKAP9 gene, detecting pathogenic variants associated with Long QT syndrome type 11 (LQT11). This autosomal dominant cardiac channelopathy predisposes individuals to ventricular arrhythmias and sudden cardiac death. Our ISO 9001:2015 certified laboratory offers 99.9% diagnostic accuracy, VIP mobile phlebotomy with temperature-controlled cold-chain home collection, pre- and post-test genetic counselling by a Consultant Medical Geneticist, and direct insurance verification via WhatsApp.
Test Overview & Methodology
Long QT syndrome type 11 (LQT11) is caused by mutations in the AKAP9 gene, which encodes A-kinase anchor protein 9, a critical scaffold protein that regulates cardiac ion channel phosphorylation and membrane expression. Pathogenic variants in AKAP9 disrupt normal cardiac repolarization, prolonging the QT interval and increasing the risk of torsade de pointes and sudden cardiac death. This NGS-based test provides comprehensive coverage of all coding exons and intron-exon boundaries, enabling detection of missense, nonsense, frameshift, splice-site, and synonymous variants with clinical-grade confidence.
| Feature | Our Test (NGS Advantage) | Standard Alternative Assay |
|---|---|---|
| Precision | >99.9% sensitivity & specificity (full gene) | Limited to known hotspots; risk of missing novel variants |
| Methodology | Next-Generation Sequencing (NGS) โ whole AKAP9 coding region | Sanger sequencing of selected exons or SNP genotyping |
| Turnaround Time | 3โ4 Weeks | 4โ6 Weeks |
| Clinical Coverage | Detects all coding variants (missense, nonsense, indels) per ACMG guidelines | Only common founder mutations |
Physician Insight & Safety Protocols
"As a Consultant Medical Geneticist, I emphasize that genetic results for AKAP9 must be interpreted within the full clinical context, including electrocardiographic findings, family history, and symptom profile. This test provides foundational data for risk stratification but should never be used in isolation for therapeutic decisions. Comprehensive pre- and post-test counselling is essential to ensure patients understand the implications of variant detection."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Guidance
Patients undergoing AKAP9 genetic testing should maintain all current medications unless otherwise directed by their treating physician. Beta-blocker therapy, if prescribed, must not be altered based on genetic results alone. Clinical correlation with a 12-lead ECG and specialist cardiology assessment is mandatory before any management changes.
Exclusion Criteria
This test is not recommended during acute cardiac emergencies or in patients with unstable hemodynamic status. Individuals with known bleeding disorders or anticoagulant therapy should inform the phlebotomist prior to sample collection. If you experience syncope, seizure-like activity, or palpitations, seek immediate emergency care without waiting for genetic test results.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the AKAP9 genetic test for Long QT syndrome?
This NGS test identifies pathogenic variants in AKAP9, enabling precise diagnosis of Long QT syndrome type 11, guiding treatment decisions such as beta-blocker therapy or ICD implantation, and facilitating cascade screening of at-risk family members. The test achieves >99.9% sensitivity and specificity for coding region variants.
2. How long do results take and what does the report include?
Results are typically available within 3โ4 weeks from sample receipt. The comprehensive report includes variant classification according to ACMG/AMP guidelines, computational pathogenicity predictions, population frequency data, and clinical recommendations for cardiac evaluation and family screening.
3. Is this test covered by UAE insurance?
Coverage varies by insurer and policy. Many UAE health insurance plans include genetic testing for diagnosed cardiac conditions. We provide direct pre-authorization verification via WhatsApp at +971 54 548 8731. Please contact us to confirm your specific coverage details.
4. What sample type is required and how is it collected?
The test requires a peripheral whole blood sample collected in an EDTA tube. Our VIP mobile phlebotomy service provides temperature-controlled cold-chain home collection daily from 8 AM to 11 PM. Alternatively, samples can be collected at our Dubai Healthcare City facility.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed solely for diagnostic purposes with explicit patient consent. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility ensures that every step of the testing lifecycle meets the highest standards of confidentiality and clinical integrity.
Clinical & Logistical Metadata
| Test Name | AKAP9 Gene Long QT Syndrome Type 11 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Saliva |
| Methodology Used | Next-Generation Sequencing (NGS) โ Complete AKAP9 Coding Region |
| ICD-10-CM Code | I45.81 |
| LOINC Code | 92884-7 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
Preparation Required
["Maintain current medications unless directed otherwise", "Inform phlebotomist of bleeding disorders or anticoagulant therapy"]
Medically Reviewed by Dr. Lina Osama Zaki Quteineh
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians